FaZe Clan Completes Combination With B. Riley Principal 150 Merger Corp
Trading to commence on NASDAQ under the ticker "FAZE" on Wednesday, July 20, 2022
LOS ANGELES and NEW YORK, July 20, 2022 /PRNewswire/ -- FaZe Clan Inc. ("FaZe Clan"), the interactive lifestyle
MEC Announces Appointment Of Jag A. Reddy As President & CEO
Current Independent Director Timothy L. Christen Named Non-Executive Chair
MAYVILLE, Wis.--(BUSINESS WIRE)-- Mayville Engineering Company (NYSE:MEC) (the “Company” or “MEC”), a leading U.S.-based
Abbott Laboratories Q2 Adj. EPS $1.43 Beats $1.12 Estimate, Sales $11.30B Beat $10.29B Estimate
Abbott Laboratories (NYSE:ABT) reported quarterly earnings of $1.43 per share which beat the analyst consensus estimate of $1.12 by 27.68 percent. This is a 22.22 percent increase over earnings of $1.17 per share from
Healthcare Services Group Q2 EPS $0.09 Misses $0.12 Estimate, Sales $424.90M Miss $426.72M Estimate
Healthcare Services Group (NASDAQ:HCSG) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.12 by 25 percent. This is a 30.77 percent decrease over earnings of $0.13 per share
Baker Hughes Q2 Adj. EPS $0.11 Misses $0.22 Estimate, Sales $5.00B Miss $5.34B Estimate
Baker Hughes (NYSE:BKR) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.22 by 50 percent. This is a 10 percent increase over earnings of $0.10 per share from the same
Merck Provides Update On Phase 3 KEYNOTE-412 Trial In Unresected Locally Advanced Head And Neck Squamous Cell Carcinoma; Trial Did Not Meet Primary Endpoint Of Event-Free Survival
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-412 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, with concurrent
